Celgene’s Otezla Gets Preliminary Nod From NICE At Second Attempt
Executive Summary
Celgene’s near-blockbuster oral psoriasis drug Otezla is cleared by NICE in a second draft guidance for use in severe psoriasis, after the company comes up with an acceptable patient access scheme.